- United States
- /
- Healthcare Services
- /
- NYSE:NEUE
NeueHealth Second Quarter 2024 Earnings: US$6.42 loss per share (vs US$8.55 loss in 2Q 2023)
NeueHealth (NYSE:NEUE) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$226.0m (down 24% from 2Q 2023).
- Net loss: US$53.0m (loss narrowed by 22% from 2Q 2023).
- US$6.42 loss per share (improved from US$8.55 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NeueHealth Earnings Insights
Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Healthcare industry in the US.
Performance of the American Healthcare industry.
The company's shares are down 22% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 5 warning signs for NeueHealth (of which 3 shouldn't be ignored!) you should know about.
Valuation is complex, but we're here to simplify it.
Discover if NeueHealth might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:NEUE
NeueHealth
A healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States.
Fair value with imperfect balance sheet.
Similar Companies
Market Insights
Weekly Picks

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fiducian: Compliance Clouds or Value Opportunity?
Willamette Valley Vineyards (WVVI): Not-So-Great Value
Recently Updated Narratives
Halyk Bank of Kazakhstan will see revenue grow 11% as their future PE reaches 3.2x soon
Silver's Breakout to over $50US will make Magma’s future shine with drill sampling returning 115g/t Silver and 2.3 g/t Gold at its Peru Mine
SEGRO's Revenue to Rise 14.7% Amidst Optimistic Growth Plans
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
